drugset / Trial / NCT00931255
Tacrolimus to Sirolimus Conversion for Delayed Graft Function
Phase 4
Terminated
32 enrolled
University of Maryland, Baltimore
Wyeth is now a wholly owned subsidiary of Pfizer · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective of this study is to evaluate the safety and efficacy of conversion from tacrolimus to sirolimus early after kidney transplantation in patients with delayed graft function (DGF)and slow graft function (SGF) in improving graft function and delaying chronic allograft nephropathy. The investigators hypothesize that conversion from tacrolimus to sirolimus in renal transplant recipients with DGF/SGF in early months after surgery will improve graft function and decrease the progression of graft fibrosis.
Timeline
- Start
- 2009-04
- Primary completion
- 2014-06
- Completion
- 2014-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sirolimus | Small molecule | 5 mg | Oral |
| Comparator | Tacrolimus | Small molecule | — | Oral |
Indications
No indication recorded.